Nasdaq Grph News Today

Graphite Bio (NASDAQ:GRPH – Get Free Report) and Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability. Insider & Institutional Ownership 54.3% of Graphite […]

Graphite Bio, Inc. (NASDAQ:GRPH – Get Free Report) was the recipient of a significant increase in short interest in August. As of August 31st, there was short interest totalling 1,060,000 shares, an increase of 7.0% from the August 15th total of 990,500 shares. Based on an average trading volume of 151,300 shares, the days-to-cover ratio […]

Graphite Bio (NASDAQ:GRPH – Get Free Report) and Talaris Therapeutics (NASDAQ:TALS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Analyst Ratings This is a breakdown of […]

Graphite Bio, Inc. (NASDAQ:GRPH – Get Free Report) saw a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling 990,500 shares, a decrease of 13.1% from the July 31st total of 1,140,000 shares. Based on an average daily trading volume, of 151,000 shares, the days-to-cover […]

Graphite Bio, Inc. (NASDAQ:GRPH – Free Report) – Stock analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Graphite Bio in a note issued to investors on Tuesday, July 11th. Cantor Fitzgerald analyst O. Brayer anticipates that the company will post earnings of ($0.61) per share for the year. […]

Shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) have earned an average rating of “Hold” from the nine analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and eight have assigned a hold recommendation to the company. The average 1-year price target among analysts […]

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Research analysts at Cantor Fitzgerald decreased their FY2023 earnings per share (EPS) estimates for Graphite Bio in a research report issued on Tuesday, May 16th. Cantor Fitzgerald analyst O. Brayer now forecasts that the company will post earnings per share of ($0.99) for the year, down from […]

Shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) have been given an average rating of “Hold” by the nine analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and eight have given a hold rating to the company. The average 1-year price target among […]

Lodestar Private Asset Management LLC purchased a new stake in shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 14,199 shares of the company’s stock, valued at approximately $47,000. A number of other hedge funds and other institutional investors have also bought and sold […]

Graphite Bio (NASDAQ:GRPH – Get Rating) and Compugen (NASDAQ:CGEN – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Volatility and Risk Graphite Bio has a beta of 0.01, […]